2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.18 Impact of Prophylactic use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancer: A Cohort Study

P4.11E.18 Impact of Prophylactic use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancer: A Cohort Study

Back to course

Pdf Summary

This cohort study explored the impact of prophylactic PEG-rhG-CSF on patients with advanced non-small cell lung cancer (NSCLC) undergoing first-line immunochemotherapy. The aim was to determine the effect on progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and drug safety.<br /><br />The study involved 127 NSCLC patients at Shengjing Hospital, with 48 patients in the treatment group receiving prophylactic PEG-rhG-CSF and 79 in the control group without it. The treatment involved one cycle administered 48 hours post-immunochemotherapy, which comprises a PD-1 inhibitor plus chemotherapy. Patients were observed over a median of 14.3 months.<br /><br />Results showed that median PFS was similar across groups, at 12.7 months for the treatment group and 12.2 months for the control group, indicating no statistical difference (HR 0.88, p=0.85). The ORR in the treatment group was 64.6%, slightly higher than the control group at 60.8% (p=0.67), while disease control rates (DCR) were almost identical across both groups (97.5% treatment vs. 97.9% control).<br /><br />In a propensity score-matched subset, the results were consistent, with median PFS slightly lower in the treatment (9.5 months) compared to the control group (10.8 months, HR 0.95, p=0.89). However, multivariate Cox regression across all patients indicated longer OS linked to less antibiotic use (HR 0.43, p=0.016) and a decreased neutrophil-to-lymphocyte ratio (HR 0.47, p=0.037).<br /><br />Adverse events were mitigated in the treatment group, experiencing fewer cases of severe leukopenia and granulocytopenia, and reduced antibiotic use (14.6% compared to 22.8% in the control).<br /><br />Ultimately, prophylactic PEG-rhG-CSF did not impair the efficacy of immunochemotherapy and showed a reduction in severe neutropenia incidents, indicating benefits concerning certain safety outcomes without impacting treatment efficiency.

Asset Subtitle

Cheng Han

Meta Tag

Speaker Cheng Han

Topic Metastatic NSCLC – Immunotherapy

Keywords

NSCLC

prophylactic PEG-rhG-CSF

immunochemotherapy

progression-free survival

overall survival

objective response rate

drug safety

adverse events

Shengjing Hospital

neutropenia